Beta adrenergic blocking and cardiovascular properties of two new substances, Kö 1313 and Kö 1366.
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002302:Cardiac Output / Q000187:drug effects; D002319:Cardiovascular System / Q000187:drug effects*; D004285:Dogs; D004336:Drug Antagonism; D004983:Ethanolamines / Q000494:pharmacology; D006321:Heart / Q000187:drug effects / Q000294:innervation; D006339:Heart Rate / Q000187:drug effects; D006584:Hexamethonium Compounds / Q000494:pharmacology; D007545:Isoproterenol / Q000037:antagonists & inhibitors / Q000494:pharmacology; D009119:Muscle Contraction / Q000187:drug effects; D009130:Muscle, Smooth / Q000187:drug effects; D010210:Papillary Muscles / Q000502:physiology; D011433:Propranolol / Q000494:pharmacology*; D013564:Sympathetic Nervous System / Q000502:physiology; D013565:Sympatholytics / Q000494:pharmacology*; D014132:Trachea / Q000187:drug effects; D016276:Ventricular Function
D000319:Adrenergic beta-Antagonists; D004983:Ethanolamines; D006584:Hexamethonium Compounds; D013565:Sympatholytics; D011433:Propranolol; D007545:Isoproterenol